Adagene Inc. (ADAG)
ADAGNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$2.13
0.0000 (0.00%) today
Regular session, Nov 12, 11:00 AM ET
- Market cap
- $140.69m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $2.02 to $2.28
- 52-week range
- $1.50 to $4.85
- Average volume
- –
- Previous close
- $2.13
Analysts
5 coveringBuy4 buy, 1 hold, 0 sell
Targets a year out average $8.50, +299.1% from here
Earnings
next estimate $-0.0800Next report
Financials
| Quarter | Dec 2020 |
|---|---|
| Revenue | $391.0k |
| Gross profit | $391.0k |
| Operating income | -$12.45m |
| Net income | -$12.77m |
News
8 latest- Adagene Inc. Announces Completion of Phase 2 Enrollment of Muzastotug and Expected US$8.0 million Second Closing of Sanofi InvestmentFintel · 3 days ago
- Adagene Begins Phase 1 Trial Of Muzastotug Plus INCA33890 In MSS Colorectal Cancer; Stock Up RTTNews · Oct 28, 2026
- Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal CancerMarketBeat · Oct 25, 2026
- Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 CatalystsMarketBeat · Oct 16, 2026
- Adagene Gains NMPA Clearance On Phase 1 For ADG138 In Solid Tumors, Set To Begin In Q4 '26 RTTNews · Sep 22, 2026
- Chardan Capital Initiates Coverage of Adagene Inc. - Depositary Receipt at BuyFintel · Sep 10, 2026
- Add Up The Pieces: PGJ Could Be Worth $33BNK Invest · Jun 18, 2026
- Adagene (ADAG) Upgraded to Buy: Here's What You Should KnowZacks · Jun 5, 2026
The company
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody precision masking technology in multiple approaches at the vanguard of science. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody, SAFEbody, and POWERbody technologies, Adagene's highly differentiated pipeline features novel immunotherapy programs. The company's SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- Asia
- Website
- adagene.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.